CVM: Cel-Sci Corporation Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 8, 2:14 PM CEL-SCI Corporation (CVM -2.5%) isn't getting much of a lift today, despite its announcement that collaborators at the National Institute of Allergy and Infectious Diseases have submitted for publication the results from efficacy studies in animals using CVM's H1N1 activated dendritic cells to treat the H1N1 bird flu virus. This work may possibly also be applicable to the new H7N9 bird flu strain currently detected in China, but no definitive statement has yet been made to that effect. Comment! [Healthcare, On the Move, Global & FX]
Friday, February 8, 4:39 PM CEL-SCI (CVM) reports a Q1 loss of $0.02, in-line with estimates and even with a loss of $0.02 reported for Q1 2012. Net losses were $2.3M versus losses of $4.2M during the prior year period. R&D expenses increased by 25% Y/Y, largely due to the increased level of activity associated with conducting Phase III clinical studies. Shares -0.5% AH. 1 Comment [Healthcare, Earnings, Breaking News]
Thursday, January 31, 12:47 PM CEL-SCI (CVM +2.3%) gains after announcing that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease. In addtion to finding an absence of tumors in lymph nodes or peritoneal membranes, the vaccine also demonstrated a reduction in the number of tumors and tumor mass. Comment! [Healthcare, On the Move]
Friday, November 30, 2012, 3:10 PM Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company expressed confidence about the outlook for Phase III trials of its Multikine immunotherapy treatment for head and neck cancer. The company also said it plans to increase the number of patient recruitment centers for the trials to at least 50, comapred with a current 36. 3 Comments [Healthcare, On the Move]
Wednesday, June 27, 2012, 10:44 AM Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for head and neck cancer is performing well in Phase 3 trials. "Based on everything that we've seen in the clinic so far, if we continue to see the same results, we will have the first non-toxic cancer therapy," Kersten tells eHealth Radio. Comment! [Healthcare, On the Move]
Wednesday, March 21, 2012, 9:14 AM Premarket gainers: ASGN +25%. FSII +15%. USG +13%. YPF +9%. HIG +7%. LNKD +6%. CVM +6%. LXRX +5%. LGF +3%.
Losers: AGO -10%. BHI -4%. ZLCS -3%. STP -3%. PHG -3%. Comment! [On the Move]
Tuesday, February 7, 2012, 9:00 AM Premarket gainers: CSTR +19%. CVM +11%. SPF +10%. SHPGY +5%. S +5%. AMLN +4%. NBG +4%. PRGO +3%. HGSI +3%. CLF +3%. CHU +3%.
Losers: NSU -22%. CFX -10%. ASTX -10%. BPAX -6%. LPL -5%. THLD -5%. SBH -4%. ALU -4%. ZOLT -4%. FRO -3%. VHPM -3%. CTIC -3%. Comment! [On the Move]
Monday, January 23, 2012, 1:09 PM Cel-Sci Corporation (CVM +8%) pops after saying late Friday that phase III clinical trials for its cancer drug Multikine were launched in dozens of hospitals located in eight countries on three continents. Comment! [Healthcare, On the Move]
Monday, January 23, 2012, 9:00 AM Premarket gainers: MFN +29%. CVM +10%. BVSN +9%. CHK +7%. FRO +5%. SWN +5%. CGO +3%. NBG +3%. FST +3%. DANG +3%. LYG +3%.
Losers: FSC -4%. RIMM -4%. NFLX -3%. SIRI -3%. Comment! [On the Move]
Wednesday, January 18, 2012, 9:10 AM Premarket gainers: UEPS +31%. CVM +16%. CBRX +16%. KUTV +11%. LLTC +8%. ZLTQ +7%. NBG +7%. WFR +5%. ING +4%. FRO +4%. HEK +3%. STM +3%. YHOO +3%. OMX +3%.
Losers: PSLV -10%. RIMM -6%. PCX -5%. CREE -4%. FAST -4%. BK -3%. BGLS -3%. GEN -3%. Comment! [On the Move]
Tuesday, December 27, 2011, 12:13 PM Microcap biotech Cel-Sci (CVM +0.3%) says it's expanding the Phase III clinical trials of its Multikine investigational injection therapy to four additional European countries, including Spain, the Czech Republic, Slovakia and Croatia. Comment! [Healthcare]
Monday, December 13, 2010, 9:10 AM Premarket gainers: DNEX +20%. NSTC +20%. VLNC +9%. PZG +7%. PCBC +7%. LOCM +6%. XRA +5%. APWR +5%. HL +5%. JDSU +5%. PTIE +4%. CCME +5%. CVM +4%. IRE +4%. CHU +4%.
Losers: NKTR -11%. OCZ -7%. ZSL -6%. HBAN -4%. Comment!
Tuesday, April 13, 2010, 9:00 AM Premarket gainers: MIPI +183%. AGEN +42%. ABK +28%. CVM +20%. XOMA +19%. BPOP +16%. FNM +10%. KERX +8%. DCTH +7%. CROX +6%. TLB +5%. EXPE +5%. HK +5%. FRE +5%. AONE +4%.
Losers: CODI -8%. PALM -7%. MPW -4%. Comment!
Thursday, November 12, 2009, 9:00 AM Premarket gainers: COMS +33%. CAAS +17%. UBET +15%. YUII +10%. JDSU +7%. CVM +6%.
Losers: BRCD -12%. GMCR -11%. SAY -5%. ABK -4%. Comment!
Wednesday, November 11, 2009, 9:00 AM Premarket gainers: CHLN +42%. TOL +7%. ING +6%. RFMD +5%. MPEL +5%. HOV +5%. ALU +4%. MBI +4%. HL +4%. GSS +4%. ABK +4%.
Losers: HEB -14%. IRE -5%. M -4%. CVM -4%. Comment!
Monday, November 9, 2009, 9:00 AM Premarket gainers: EWBC +51%. ARIA +14%. RSH +11%. FUQI +10%. SAY +9%. TSFG +7%. NCS +7%. JASO +6%. DISH +6%. CVM +6%. AIB +6%. ANF +6%. RTP +5%. MBI +5%. NG +4%. LVS +4%. SLW +4%. HL +4%. GFI +4%. SWKS +4%. BHP +4%. FAS +4%. TGB 4%. XOMA +4%. Comment!

CVM Cel-Sci Corporation

CVM

Cel-Sci Corporation